Bluejay Diagnostics Inc. is a leading medical technology company dedicated to transforming patient care through pioneering diagnostic solutions that prioritize early disease detection. Utilizing a proprietary platform that integrates artificial intelligence with point-of-care testing, Bluejay significantly enhances the accuracy and speed of diagnostics, delivering timely and actionable insights to healthcare professionals. With a strong focus on research and development, the company is strategically positioned to address critical healthcare gaps and meet the increasing demand for innovative and reliable diagnostic tools in an evolving medical environment.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 48,910 |
| EBITDA | $-6.84M |
| Operating Margin | 0.00% |
| Return on Equity | -117.00% |
| Return on Assets | -62.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.88 |
| Price-to-Book | 0.33 |
| Price-to-Sales (TTM) | 54.99 |
| EV/Revenue | 5.67 |
| EV/EBITDA | -0.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.03M |
| Float | 793,440 |
| % Insiders | 5.18% |
| % Institutions | 4.07% |
Volatility is currently contracting